CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Recruiting · NCT06947460 · Registry updated 2026-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, skin disorder, systemic lupus erythematosus, systemic sclerosis, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-30 | NCT06947460 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing GoBroad Hospital | 42 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| 北京高博医院 | Beijing | China | 1 |